Extension study of TEV-56286 for multiple system atrophy
Part of Brain & nervous system clinical trials.
This trial tests whether the drug TEV-56286 continues to work for multiple system atrophy (a rare brain disorder). It is for people who already completed a previous study of the same drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed a previous study (called TV56286-NDG-20039) and attended the week 48 visit.
- If you are a woman who could become pregnant, you must have a negative pregnancy test at the start.
- Women who could become pregnant and their male partners (if fertile) must use highly effective birth control during the study and for 28 days after the last dose.
- Men who are fertile and their female partners must use highly effective birth control during the study and for 28 days after the last dose.
- You cannot be pregnant, planning to become pregnant, or breastfeeding.
- You cannot be in a vulnerable population (like being in detention or jail).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This trial tests a new antibody therapy that may target and remove abnormal proteins in the brain linked to Multiple System Atrophy (MSA). It aims to see if the treatment is safe and whether it can help slow the progression of the disease.
This program lets people who already completed a study of the drug ATH434 for multiple system atrophy continue getting the treatment. It is for patients whose doctors believe they may benefit from staying on the medication.
This trial tests a new stem cell treatment for people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions. The treatment uses stem cells from healthy donors, which may help slow down the disease.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
This study tests whether a drug called butylphthalide can safely help people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions like blood pressure. Participating may help slow the progression of symptoms and improve quality of life.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.